Drugs / MRG007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07066657 | Jul 2025 → May 2029 expected | colorectal cancer, gastric cancer, malignant pancreatic neoplasm | ArriVent BioPharma, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-01-21 | ArriVent BioPharma, Inc. | ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers arrivent.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRG007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07066657 ↗ |